Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.71 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080135 | 1.00 | AR (0.71) | ARSRD5A2KCNH2 | |
| SCHEMBL7624227 | 0.92 | AR (0.67) | ARSRD5A2KCNH2 | |
| SCHEMBL11005803 | 0.90 | AR (0.68) | ARSRD5A2KCNH2 | |
| SCHEMBL11005799 | 0.90 | AR (0.68) | ARSRD5A2KCNH2 | |
| SCHEMBL9352898 | 0.87 | SRD5A2 (0.61) | ARSRD5A2KCNH2 | |
| SCHEMBL6402703 | 0.86 | SRD5A2 (0.65) | ARSRD5A2KCNH2 | |
| SCHEMBL14271704 | 0.86 | AR (0.60) | ARSRD5A2KCNH2 | |
| SCHEMBL4630379 | 0.86 | AR (0.60) | ARSRD5A2KCNH2 | |
| SCHEMBL5213364 | 0.85 | AR (0.64) | ARSRD5A2KCNH2 | |
| SCHEMBL5213351 | 0.85 | AR (0.64) | ARSRD5A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1420796-A4 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO INC (US) | 2007-07-11 | — | — | EP | claimed |
| EP-1420796-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Merck & Co., Inc. (US) | 2004-05-26 | — | — | EP | claimed |
| US-6645974-B2 | Administering an androstamide compound; osteoporosis, anticancer agents, glandular disorders | MERCK & CO., INC. | 2003-11-11 | — | — | US | claimed |
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | claimed |
| WO-2003011302-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | claimed |
| US-6645974-B2 | Administering an androstamide compound; osteoporosis, anticancer agents, glandular disorders | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | AR, FSHR, SHBG | AR 1/4885SRD5A2 80/4885KCNH2 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.